AI-assisted evidence synthesis reveals the uneven distribution of PFAS exposure by race and income in the U.S.
An AI-assisted, human-verified evidence synthesis of the published scientific and government-monitoring literature on the human body burden of per- and polyfluoroalkyl substances (PFAS) and the uneven, race- and income-patterned distribution of industrial chemical exposure in the United States. Biomonitoring establishes that PFAS are measurable in nearly the entire US population (CDC/ATSDR NHANES, aged 12+ since 1999–2000), that legacy PFAS persist for decades despite production phase-outs — more than 96% of adolescents still carry detectable legacy compounds, weighted detection of PFHpS at 78.2% — because the carbon–fluorine bond is among the strongest single bonds in organic chemistry. Separately, proximity to polluting industrial facilities is patterned by race and income: a nationally representative analysis (Mohai et al., AJPH 2009) found Black Americans at 1.38 times the odds (adjusted OR 1.38; 95% CI 1.10–1.72) of living within a mile of such a facility after adjusting for income and education, and in FY2022 roughly half the population within a mile of a Superfund site were people of color. Louisiana's 'Cancer Alley' is the acute domestic case: a 2025 peer-reviewed study using measured (not modeled) air concentrations found corridor cancer risks up to 11.6× the EPA's 2020 estimates (median ~5×), with ethylene oxide, chloroprene and formaldehyde accounting for 63–96.9% of estimated risk, and in 2023 the EPA itself found significant evidence of disparate impacts on Black residents. The load-bearing frame is associational: biomonitoring establishes presence and distribution, not individual causation; the proximity and cancer-risk findings are strong ecological associations vulnerable to confounding and exposure misclassification. What the record supports is that industrial chemical exposure is ubiquitous, persistent, and concentrated among populations with the least capacity to change it. This deposit is the full evidence review (the citable version of this work); a summary brief is published alongside it. Ungated and fully cited; not peer-reviewed and not medical advice. Published by Holistic Quality LLC at https://holisticquality.io/research/pfas-body-burden-full .Competing interests: the author, Levi Robey, is the founder and principal of Holistic Quality LLC, the commercial publisher of this report, which develops regulator-facing safety-data and compliance products in subject areas that include environmental and chemical exposure; a sibling property under the same parent entity, the Institute for Cognitive Sovereignty, may cite this report in public advocacy. These relationships constitute a financial and intellectual competing interest. To mitigate it, every quantitative claim and citation was independently verified against its published source (fetch-no-memory), four claims carried over from an earlier advocacy draft were corrected or dropped, the report states explicitly where the evidence is associational and where causation is not established, and the author retained full and sole editorial control — no commercial customer or third party reviewed or influenced the content. Funding: none; produced internally by Holistic Quality LLC with no external, grant, or third-party funding.
No takes yet. Share an insight, caveat, or question.
Levi Robey (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: